Alaunos Therapeutics Inc (TCRT) - Total Liabilities
Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) has total liabilities worth $813.00K USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alaunos Therapeutics Inc - Total Liabilities Trend (2001–2025)
This chart illustrates how Alaunos Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See TCRT working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Alaunos Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Alaunos Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Archies Limited
NSE:ARCHIES
|
India | Rs602.64 Million |
|
Brera Holdings PLC Class B Ordinary Shares
NASDAQ:BREA
|
USA | $6.30 Million |
|
Schroder Japan Growth Fund
LSE:SJG
|
UK | GBX3.69 Million |
|
Americore Resources Corp.
V:AMCO
|
Canada | CA$123.70K |
|
IMPRENDIROMA S.P.A.
F:Y37
|
Germany | €22.61 Million |
|
East Side Games Group Inc
TO:EAGR
|
Canada | CA$17.63 Million |
|
Au Gold Corp
V:AUGC
|
Canada | CA$49.23K |
|
Randgold Exploration
JSE:RNG
|
South Africa | ZAC10.99 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Alaunos Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TCRT stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alaunos Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alaunos Therapeutics Inc (2001–2025)
The table below shows the annual total liabilities of Alaunos Therapeutics Inc from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $813.00K | +17.49% |
| 2024-12-31 | $692.00K | -64.62% |
| 2023-12-31 | $1.96 Million | -92.59% |
| 2022-12-31 | $26.38 Million | -28.33% |
| 2021-12-31 | $36.81 Million | +64.59% |
| 2020-12-31 | $22.36 Million | +58.56% |
| 2019-12-31 | $14.10 Million | +48.67% |
| 2018-12-31 | $9.49 Million | -95.31% |
| 2017-12-31 | $202.41 Million | +10.22% |
| 2016-12-31 | $183.65 Million | +176.77% |
| 2015-12-31 | $66.35 Million | +482.25% |
| 2014-12-31 | $11.40 Million | -49.06% |
| 2013-12-31 | $22.37 Million | -36.01% |
| 2012-12-31 | $34.96 Million | -4.22% |
| 2011-12-31 | $36.50 Million | +17.87% |
| 2010-12-31 | $30.97 Million | +43.15% |
| 2009-12-31 | $21.63 Million | +270.79% |
| 2008-12-31 | $5.83 Million | -8.22% |
| 2007-12-31 | $6.36 Million | +113.37% |
| 2006-12-31 | $2.98 Million | +30.07% |
| 2005-12-31 | $2.29 Million | +10782.70% |
| 2004-12-31 | $21.05K | -18.17% |
| 2003-12-31 | $25.72K | +44.21% |
| 2002-12-31 | $17.84K | +224.27% |
| 2001-12-31 | $5.50K | -- |
About Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. The company develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. It also develops hunTR TCR discovery platform to target driver mutations. Alaunos Th… Read more